These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37991563)

  • 41. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
    Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
    Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unexpectedly high incidences of chronic non-bacterial as compared to bacterial osteomyelitis in children.
    Schnabel A; Range U; Hahn G; Siepmann T; Berner R; Hedrich CM
    Rheumatol Int; 2016 Dec; 36(12):1737-1745. PubMed ID: 27730289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
    Morgan GJ; Child JA; Gregory WM; Szubert AJ; Cocks K; Bell SE; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Wu P; Davies FE;
    Lancet Oncol; 2011 Aug; 12(8):743-52. PubMed ID: 21771568
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bone-site-specific responses to zoledronic acid.
    Vermeer J; Renders G; van Duin MA; Jansen I; Bakker LF; Kroon SA; de Vries TJ; Everts V
    Oral Dis; 2017 Jan; 23(1):126-133. PubMed ID: 27706930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
    Calvo-Villas JM; Tapia Torres M; Govantes Rodríguez J; Carreter de Granda E; Sicilia Guillén F
    Med Clin (Barc); 2006 Oct; 127(15):576-9. PubMed ID: 17153267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term follow-up of children with chronic non-bacterial osteomyelitis-assessment of disease activity, risk factors, and outcome.
    Reiser C; Klotsche J; Hospach T; Heubner G; Windschall D; Trauzeddel R; Groesch N; Niewerth M; Minden K; Girschick H
    Arthritis Res Ther; 2023 Nov; 25(1):228. PubMed ID: 38017565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
    J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee.
    Müller F; Appelt KA; Meier C; Suhm N
    Knee Surg Sports Traumatol Arthrosc; 2020 Feb; 28(2):408-417. PubMed ID: 31273410
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The peculiarities and treatment outcomes of the spinal form of chronic non-bacterial osteomyelitis in children: a retrospective cohort study.
    Kostik MM; Kopchak OL; Maletin AS; Mushkin AY
    Rheumatol Int; 2020 Jan; 40(1):97-105. PubMed ID: 31754777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM; Harker WG; Beck JT; Bosserman L; Vogel C; Seidler C; Jin L; Warsi G; Argonza-Aviles E; Hohneker J; Ericson SG; Perez EA
    Cancer; 2012 Mar; 118(5):1192-201. PubMed ID: 21987386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral administration of alendronate and vitamin D3 for the treatment of chronic non-bacterial osteomyelitis of the jaw.
    Yang X; Zhou K; Shang W; Song K
    Int J Oral Maxillofac Surg; 2020 Dec; 49(12):1595-1598. PubMed ID: 32680809
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series.
    Sivendran S; Harvey H; Lipton A; Drabick J
    Int J Hematol; 2011 Jun; 93(6):782-786. PubMed ID: 21519845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.